Berlin-based ProBioGen has closed a deal with Asahi Kasei Pharma (TYO:2502) to collaborate on biologics. The German company said it will use its proprietary cell line development platform and transposase technology to support Tokyo-based Asahi Kasei’s biologics pipeline development.
“We are enchanted to work with Asahi Kasei Pharma on one of their key projects and are convinced that we can make a difference by applying our inventive technologies,” said Dr. Gabriele Schneider, chief business officer at ProBioGen in prepared remarks.
Last month, ProBioGen announced that it had signed a similar agreement with Ladenburg, Germany-based Heidelberg Pharma related to antibody targeted amanitin conjugate molecules.
The company also announced that Schlieren, Switzerland-based ImmunOs Therapeutics was using ProBioGen’s proprietary pathway modulator technology to boost the protein yield of candidates in that company’s pipeline of novel complex recombinant proteins.